Acrivon Therapeutics, Inc. · NASDAQ:ACRV

Citadel Advisors LLC's stake in Acrivon Therapeutics, Inc. fell to 4.90% (Schedule 13G/A)

Event Sep 30, 2025 · Filed Nov 14, 2025

Citadel Advisors LLC's stake in Acrivon Therapeutics, Inc. fell to 4.90%, 1,541,326 shares, as a passive investor on Sep 30, 2025. Filed Nov 14, 2025 (Schedule 13G/A).

Stake
4.90%
Shares
1,541,326
Intent
Passive
What changed
Fell below 5%
Filed together
7 holders

The filing in full

HolderStakeShares
Citadel Advisors LLC4.90%1,541,326
Citadel Advisors Holdings LP4.90%1,541,326
Citadel GP LLC4.90%1,541,326
Citadel Securities LLC0%39
Citadel Securities Group LP0%39
Citadel Securities GP LLC0%39
Kenneth Griffin4.90%1,541,365

Source

View original at SEC

Related